CRISPR Therapeutics AG (CRSP): $123.86

0.24 (+0.19%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CRSP to Watchlist
Sign Up

Industry: Biotech


Ranked

of 486

in industry

CRISPR Therapeutics AG (CRSP) Price Targets From Analysts

The tables below show price targets and recommendations from analysts covering CRISPR Therapeutics AG.

Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
18 $220 $55 $158.78 $128.76 23.31%

The Trend in the Analyst Price Target


Over the past 29 weeks, CRSP's average price target has gone up $56.16.

CRSP reports an average of 7.58% for its upside potential over the past 51 weeks.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-06-01 18 220 55 158.78 115.80 37.12%
2021-04-19 17 210 45 157.12 115.04 36.58%
2021-04-17 17 210 45 157.12 118.56 32.52%
2021-03-17 16 210 45 157.56 131.10 20.18%
2021-03-13 16 210 45 157.56 130.61 20.63%
2021-01-25 16 210 45 146.56 181.24 -19.13%
2021-01-23 16 210 45 146.56 188.49 -22.25%
2021-01-16 16 210 45 146.56 199.88 -26.68%
2020-11-26 16 140 45 102.63 110.00 -6.7%
2020-11-11 16 140 45 102.62 100.64 1.97%
2020-10-28 16 140 47 102.75 94.71 8.49%
2020-10-04 13 140 31 98.54 79.67 23.69%
2020-09-01 14 140 31 95.21 93.42 1.92%
2020-07-28 14 140 31 95.21 86.40 10.2%
2020-07-13 14 140 31 81.75 86.23 -5.2%
2020-06-22 13 105 31 77.27 72.02 7.29%
2020-06-22 14 105 31 75.75 72.02 5.18%
2020-06-18 14 105 31 74.46 67.34 10.57%
2020-06-09 14 104 31 73.82 NA NA%

CRSP Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1.6 6 8 5 1 1 21

The Trend in the Broker Recommendations


Over the past 35 weeks, CRSP's average broker recommendation rating worsened by 0.25.

Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.

  • The variance in analysts' estimates of CRSP is lower than 4.48% of all US stocks.
  • CRISPR Therapeutics AG's number of analysts covering the stock is higher than 95.97% of Pharmaceutical Products stocks.
  • CRSP has a higher average analyst price target than 95.68% of Pharmaceutical Products stocks.
  • The upside potential (average analyst target price relative to current price) of CRSP is greater than 87.13% of stocks in the large market cap category.

In the Pharmaceutical Products industry, IONS, AMGN and HALO are the three stocks most similar to CRISPR Therapeutics AG regarding the price target and analyst recommendation information presented here.

Is CRSP a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.7203 seconds.